GlassScriptPhysician profile
Anthony C Delach
NPI 1245538438
$42,147.10
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $4,557 · 2021: $14K · 2022: $5,166.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25,967.58 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $14,563.37 | 2019-2022 | |
| Neos Therapeutics, LP | $815.58 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.77 | 2019-2021 | |
| Tris Pharma INC | $267.41 | 2019-2020 | |
| Adlon Therapeutics L.P. | $75.41 | 2019-2021 | |
| Corium, LLC | $64.46 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $29.55 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $23.53 | 2019 | |
| Shire North American Group INC | $14.05 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.39 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Delach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.